Compare Revvity Inc (RVTY) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Atlassian Corporation PLC — how do they compare? Revvity Inc trades at $116.32 (market cap $12.91B), while Atlassian Corporation PLC trades at $154.03 (market cap $39.10B). The key difference: Atlassian Corporation PLC is far larger — about 3× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| RVTY | TEAM | |
|---|---|---|
Market Cap | $12.91B | $39.10B |
Sector | Technology | Technology |
52-Week High | $117.75 | $182.36 |
52-Week Low | $82.26 | $57.15 |
Enterprise Value | $15.23B | $39.09B |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Atlassian (TEAM) trades at $152.49, up 0.41% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported strong Q4 2026 earnings, beating estimates with 28% revenue growth and achieving its first full year of GAAP profitability. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a consensus price target of $161.93.
The outlook is favorable given accelerating cloud revenue and AI platform adoption, though risks include high valuation multiples and potential growth deceleration. Net losses have narrowed significantly, but the stock's EV/EBITDA of 184.26 suggests premium pricing. Continued execution on enterprise deals and margin expansion are key for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
